| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2020-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f149082e9960214d1b4a2af9f3ed8591
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83cd4141b194e641db0c891292772f39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c73532c0329f0ff14e8d1fa9f1e8fc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee7eec0bfe233fdd4cabb3ef1ea8a2a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f213f11a2b40c43239b842b1529b806b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26be6b7e4e6b821a707b7b789f2225ba |
| publicationDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202123941-A |
| titleOfInvention |
Use of an mdm2 inhibitor for the treatment of myelofibrosis |
| abstract |
The invention relates to the use of an MDM2 inhibitor in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an MDM2 inhibitor and b) at least one further therapeutic agent, preferably ruxolitinib or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2019-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |